Depressive Disorder News and Research

RSS

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

MDD with subthreshold hypomania ‘should be merged with bipolar II’

Patients with major depressive disorder plus subthreshold hypomania exhibit significant differences in disease course, symptoms, treatment-seeking rates and other characteristics compared with those with major depression alone, research shows.

10 Oct 2012

Major depression goes unnoticed in pregnant women

Healthcare professionals looking after pregnant women should maintain a high level of awareness for the possibility of major depressive disorder, say US researchers who found the condition frequently goes undetected.

5 Oct 2012

Fluoxetine increases offensive aggression and alters brain development in adolescent hamsters

Fluoxetine was the first drug approved by the FDA for major depressive disorder (MDD) in children and adolescents, and to this date, it remains one of only two selective serotonin reuptake inhibitors (SSRIs) registered for treatment of MDD in children and adolescents, despite reports that indicate this class of drugs is associated with side effects, such as agitation, hostility and aggression.

3 Oct 2012

BD family history risk factor for recurrent episodes in MDD

A family history of bipolar disorder increases the likelihood of recurrent episodes of hypomania or mania in individuals with prior major depressive disorder, suggest findings published in Bipolar Disorders.

1 Oct 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Executive attention deficits in youth at risk for mood disorders

Young people with a parental history of bipolar disorder or major depressive disorder have slower reaction times on tests of executive attention than those with mentally healthy parents, US researchers report.

20 Sep 2012

Mood disorder, anxiety risk elevated in children with mood disordered parents

Children with a parental history of bipolar disorder or major depressive disorder are at increased risk for any mood or anxiety disorder, research shows.

19 Sep 2012

Trigeminal Nerve Stimulation: an interview with Dr Leon Ekchian, President and CEO of NeuroSigma

Trigeminal Nerve Stimulation (TNS) is a novel medical treatment in which mild electrical signals stimulate branches of the trigeminal nerve in order to change the activity of targeted brain regions. The trigeminal nerve is the largest cranial nerve, and provides sensation to the face and head. Because it is a large sensory nerve, the trigeminal offers a high-bandwidth pathway for electrical signals to enter the brain. The brain areas targeted by TNS are known to play key roles in seizures, mood, and attention.

14 Sep 2012

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.

5 Sep 2012

Breastfeeding may lower risk for depression in adulthood

A study published in the last issue of Psychotherapy and Psychosomatics examines the relationship between breastfeeding and onset of depression in adulthood.

5 Sep 2012

New evidence reveals possibility of mood-enhancing effects associated with some flavors

New evidence reveals the possibility of mood-enhancing effects associated with some flavors, stemming at least in part from natural ingredients bearing a striking chemical similarity to valproic acid, a widely used prescription mood-stabilizing drug, scientists reported here today. This effect joins those previously reported for chocolate, teas and some other known comfort foods.

20 Aug 2012